New Phase 3 PROTEUS substudy results show that adding apalutamide plus androgen deprivation therapy (ADT) before and after surgery reduces the risk of prostate cancer recurrence or death by 62% compared to surgery alone in high-risk localized or locally advanced prostate cancer patients. The treatment also lowered the risk of metastasis or death by 51% and doubled the number of patients free from additional therapy at three years. These findings, presented at ESMO 2026 and building on earlier ASCO data, suggest perioperative apalutamide plus ADT could improve long-term outcomes beyond surgery alone. Further follow-up is ongoing to assess overall survival.
Following Johnson & Johnson's announcement of promising Phase 3 results for ERLEADA® in prostate cancer treatment, JNJ shares are trading at USD 263.81 on Pluang as of Oct 24, 2026 20:02 WIB, down 1.42% for the day. The stock holds a market cap of $635.07 billion and a dividend yield of 2.03%, with a typical hold time of 129 days. Despite the recent decline, investor interest remains active with 78% of orders to sell and 22% to buy.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Procter & Gamble's stock surged 6% following a quarterly earnings beat with core EPS of $2 and net sales of $23.28 billion, surpassing expectations. The company’s price increases are holding up well, driven by resilient higher-income consumers, thoug...
